Positive spate stock price innovation Gao Haixiang drug tycoon shareholders to reduce the opportunity

In the face of a very likely great boon, Hai Xiang Pharmaceutical (002099, closing price of 25.98 yuan), including institutions, capital and other funds are strongly sought after, share prices in this week to create a record high, but ironically, the company's status at the hands of large shareholders are seized with the opportunity to hold up the banner of reducing.　　Today, Hai Xiang Pharmaceutical released a reduction notice, said the holding shareholder Robonpeng on August 31 through the bulk trading system to reduce the company shares 3.079 million shares, accounting for 1.92% of total equity.　　This Tuesday, Hai Xiang Pharmaceutical industry has a total of two large transactions, Robonpeng sold 1.879 million shares, 1.2 million shares, the transaction price of 24.38 yuan, the day of the Sea Xiang pharmaceutical close to 26.96 yuan, the discount range of up to 9.57%. "In accordance with the current ' regulation ' of the bulk trading market, the price is basically in the same day near the drop in price, the recipient side to remove to the intermediary costs, generally around 4%, Hai Xiang Pharmaceutical industry as long as the second trading day decline not more than 6%, basically have to earn."　　"A private-equity person in the bulk market is analyzing the daily economic news reporter.　　Sure enough, yesterday, Hai Xiang Pharmaceutical industry after opening independent of the market volume lower, a decline of more than 6%, the afternoon decline narrowed, closed down 3.64%. This is not the first time the controlling shareholder has been underweight this year. At the end of last year, the company announced that Robonpeng and the concerted action Zhengzhiguo in the next 6 months to sell the total shares of the total capital 5%~8.6%.　　As of June 30, 2010, the actual reduction of 12.971 million shares, accounting for 8.08% of the capital, only one step away from the upper limit, or the beginning of the second round of reducing the tide, Hai Xiang Pharmaceutical Industry Bulletin said that in the next 6 consecutive months Robonpeng and concerted action will further reduce the number of less than 5% of the shares.　　Very strange is, accompanied by the large shareholder reduction footsteps is its stock price strong climb, the buyer is no lack of institutional figure, August 2, the stock trading, buy the top 5, there are three institutions seats, in addition to the Liaoyang securities, such as the Democratic Road Sales department, such as well-known floating figures. "In fact, we are optimistic about Germany Boehringer Ingelheim International Limited (hereinafter referred to as BII) orders."　　One researcher said to the daily economic news reporter.　　Prior to that, the sea Xiang Pharmaceutical and BII signed the "Strategic Production Alliance Agreement", Haicheung become the exclusive BII for the cardiovascular primary research medicine to provide intermediates suppliers.　　"The recent surge in shares in the Hai Xiang Pharmaceutical industry may be a rumor," said the researcher.　　It is understood that the recent FDA official website released news that the FDA's blood vessel and Kidney Disease Drug Advisory Committee decided on September 20, 2010 to consider the German BII company patented drug to the listing problem. It is widely expected to pass smoothly. This marks a faster pace of Gathen in the United States, the possibility of a large number of approved before the end of the year, which for the bii production of Gathen two key intermediates of the Hai Xiang Pharmaceutical industry undoubtedly constitutes a significant positive.　　In the face of this may come the major positive, the company knows the big shareholder is in the choice of reduction, this signal for ordinary investors believe is worth reference.